Go Pro
NASDAQ:PTIX

Atrinsic 8/18/2026 Earnings Report

Atrinsic logo
$0.22 0.00 (0.00%)
As of 07/22/2026

Atrinsic EPS Results

Actual EPS
N/A
Consensus EPS
-$4.48
Beat/Miss
N/A
One Year Ago EPS
N/A

Atrinsic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atrinsic Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Atrinsic Earnings Headlines

Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
Protagenic Therapeutics swaps warrants for shares
See More Atrinsic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atrinsic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrinsic and other key companies, straight to your email.

About Atrinsic

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

View Atrinsic Profile